Apyx Medical Inc
$ 3.44
-4.44%
26 Dec - close price
- Market Cap 141,142,000 USD
- Current Price $ 3.44
- High / Low $ 3.55 / 3.41
- Stock P/E N/A
- Book Value 0.16
- EPS -0.36
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.10 %
- ROE -1.68 %
- 52 Week High 4.44
- 52 Week Low 0.76
About
Apyx Medical Inc. is an advanced energy technology company headquartered in Clearwater, Florida, focused on developing innovative medical devices for cosmetic and surgical applications. Leveraging its proprietary radiofrequency (RF) energy systems, Apyx Medical aims to enhance surgical outcomes and improve patient safety in response to critical clinical needs. The company is actively expanding its product portfolio and strategic partnerships to bolster its market presence in the evolving healthcare landscape. With a commitment to innovation and a strong emphasis on research and development, Apyx Medical is well-positioned to deliver value to its stakeholders and capitalize on emerging industry trends.
Analyst Target Price
$6.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-19 | 2024-11-08 | 2024-08-08 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-16 |
| Reported EPS | -0.05 | 0.09 | -0.1 | -0.12 | -0.14 | -0.19 | -0.22 | -0.28 | -0.13 | -0.11 | -0.1 | -0.17 |
| Estimated EPS | -0.1033 | -0.09 | -0.12 | -0.16 | -0.19 | -0.2 | -0.21 | -0.18 | -0.11 | -0.07 | -0.13 | -0.14 |
| Surprise | 0.0533 | 0.18 | 0.02 | 0.04 | 0.05 | 0.01 | -0.01 | -0.1 | -0.02 | -0.04 | 0.03 | -0.03 |
| Surprise Percentage | 51.5973% | 200% | 16.6667% | 25% | 26.3158% | 5% | -4.7619% | -55.5556% | -18.1818% | -57.1429% | 23.0769% | -21.4286% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: APYX
2025-12-16 16:09:14
Roth Capital has initiated coverage on Apyx Medical (APYX) with a 'Buy' rating and set a price target of $6.00 USD. This follows a recent upgrade by Citizens to 'Market Outperform' with an $8.00 USD price target. Apyx Medical, specializing in energy technology medical devices, has an average analyst target price of $5.75 from four analysts, implying a 51.12% upside from its current price.
2025-12-16 11:09:14
Roth/MKM has initiated coverage on Apyx Medical Corp. (NASDAQ:APYX) with a Buy rating and a $6.00 price target, citing the company's unique Renuvion technology for skin tightening. Despite Apyx not currently being profitable, the firm highlights its strong liquidity and potential for market expansion through GLP-1 drug usage and upcoming label expansions. The company recently reported strong Q3 2025 sales and launched new products, further bolstering its market position.
2025-12-12 22:08:47
Apyx Medical Corporation (NASDAQ:APYX) has filed an amendment to its Certificate of Incorporation with the Delaware Secretary of State, removing Article EIGHTH as approved by stockholders. This change was previously detailed in a proxy statement filed with the SEC. The company also reported strong Q3 2025 earnings, received an analyst upgrade, and announced the commercial launch of its Apyx One console in South Korea.
2025-12-04 05:03:52
Apyx Medical Corporation has announced the regulatory approval and commercial launch of its Apyx One console and single-use handpieces in South Korea. The company expects to begin shipping products in the fourth quarter of 2025, targeting South Korea's substantial cosmetic surgery market, which is projected to grow significantly. This launch follows strong third-quarter 2025 earnings and a recent stock upgrade by Citizens, highlighting Apyx Medical's positive momentum.
2025-12-04 05:03:52
Apyx Medical (Nasdaq: APYX) has received MFDS approval and is commercially launching its Apyx One console and single-use handpieces for cosmetic surgical procedures in South Korea, with initial shipments expected in Q4 2025. The company highlights the significant growth potential in the South Korean cosmetic surgery market, projected to reach $3.9 billion by 2033, and anticipates increased demand for body contouring due to GLP-1 weight-loss drugs. Apyx One integrates Renuvion technology with monopolar and bipolar energy, offering advanced features for enhanced procedural control.
2025-12-03 20:09:34
Apyx Medical Corporation has announced the approval and commercial launch of its Apyx One console and single-use handpieces for cosmetic surgical procedures in South Korea. This strategic move targets South Korea's growing cosmetic surgery market, estimated at $1.7 billion in 2024, expecting to capitalize on increasing demand for skin laxity solutions post-GLP-1 weight loss. Initial commercial orders for the Apyx One console are anticipated to begin shipping in Q4 2025.
